Combination Therapies
In some disease areas — primarily oncology — multiple medicines are used simultaneously or in short succession. These ‘Combination Therapies’ are a promising avenue for biomedical research but present economic challenges.
The Price of Success: Can innovative payment models support access to combination therapies in Europe?
12 November 2024
This panel considered the arguments for and against a system of differential pricing for combination therapies in Europe. They debated whether approaches to pricing in Europe…
Unlocking the Value of Combination Therapies
9 July 2024
Combination therapies (CTs) merge treatments with different mechanisms of action to achieve greater clinical benefits than the individual components alone. CTs are increasingly being used in oncology.
A Framework for Value-aligned Pricing of Combination Therapies
25 June 2024
Combination therapies can provide effective treatment options and improve patient outcomes. However, there are significant barriers to patient access to combination therapies, including the prevailing pricing models used in Europe.
Combination Therapies: A Step Forward to the Value Attribution Problem
4 January 2023
OHE convened a roundtable discussion to present and discuss recent work by OHE colleagues and collaborators on value attribution frameworks for combination therapies.
Collaborating on Payment Models to Unlock the Potential of Multi-Indication Therapies.
22 June 2022
Innovation in drug development is evolving at pace. Individual medicines are increasingly found to benefit patients in a range of indications….
Payment Models for Multi-Indication Therapies
1 November 2021
For the growing number of multi-indication medicines, access may be delayed or even denied due to challenges in linking payment with a medicine’s value across those…
A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases
1 September 2021
Medicines for rare and ultra-rare conditions face distinct economic and ethical challenges compared to medicines for more common conditions. These challenges are implicitly acknowledged by the…
Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward
1 December 2018
This report provides a detailed summary of a panel discussion held at the HTAi 2017 annual meeting in Rome on the current approaches to MIP in…
Multi-indication Pricing: Pros, Cons and Applicability to the UK
1 October 2015
Multi-indication pricing (MIP) involves setting a different price for each major indication approved for a medicine. As value is likely to differ across major indications, if…